Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives


 21st January 2011 Catalent Pharma Solutions


RESEARCH TRIANGLE PARK, NC, January 19, 2010 – Catalent Pharma Solutions will host an educational webinar featuring the Optiform™ Technologies team of Catalent experts: Dr. Joanna Bis, Dr. Pingyun Chen, and Dr. David Igo. The presentation, titled “Fit-For-Purpose Strategies for Solid-Form Discovery and Development,” will be held on Wednesday, January 26th from 10:00 a.m. to 11:15 a.m. EST. The webinar will explore the utilization of fit-for-purpose strategies in the discovery and development of solid-state forms of drug substances and highlight how these strategies influence cost, speed, and risk. During the early phases of development, the correlation between these factors has required constant consideration. The pressure to progress compounds quickly to a “go” or “no-go” decision point has driven the evolution in the early development process to the point where development strategies are now being crafted to be fit-for-purpose. As a result, this has led to an evolution in the timing and scope of activities surrounding salt, form, and co-crystal screening.

To register for the webinar, visit

For more information on the material that will be presented, visit

As the Principal Scientist, Dr. Joanna Bis works to support solid-state form development activities at Optiform™ Technologies for Catalent Pharma Solutions. Prior to this position, she worked as a principal scientist for GlaxoSmithKline in the solid form sciences department. In this role, Dr. Bis was responsible for supporting solid-state form screening and selection activities for early, middle, and late-stage drug development projects, as well as addressing solid-state issues encountered during the development of crystallization and formulation processes.

Dr. Pingyun Chen serves as the Manager of Optiform™ Technologies at Catalent Pharma Solutions. He began his pharmaceutical career in 1999 working at GlaxoWellcome. After spending one year as a principal research scientist in the crystallization process laboratory at Eli Lilly, he returned to chemical development at Glaxo Inc. (now GlaxoSmithKline, “GSK”) to provide global salt and polymorph screening and selection support of drug candidates from discovery through commercialization. Dr. Chen has given multiple presentations at national meetings, co-authored a book chapter on the application of vibrational spectroscopy in pharmaceutical development, and is named as a co-inventor on multiple patents.

As the current Director of Optiform™ Technologies at Catalent Pharma Solutions, Dr. David Igo combines novel automation tools and solid-state workflows to support the discovery and evaluation of crystalline forms, salts, and co-crystals. He began his industrial career with Glaxo Inc. in 1991 supporting various aspects of drug development including pre-formulation, product development, chemical development, materials characterization and technology development. While working at GSK, Dr. Igo co-invented a variety of high-throughput technologies utilized in solid-state screening along with a range of unique crystalline salts and solid-state forms of GSK compounds.

To learn more about the Optiform™ compound screening technology, visit

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,000 people at 29 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit

more products. better treatments. reliably supplied.™

Media contact:

Patricia McGee

T (732) 537-6407


Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |